7Baggers
 Astria Therapeutics (ATXS) Downgraded to Neutral by Cantor Fitzg  GuruFocus Wed, 12 Nov 2025 19:38:46 GMT
 ASTRIA THERAPEUTICS Earnings Results: $ATXS Reports Quarterly Earnings  Quiver Quantitative Wed, 12 Nov 2025 13:35:00 GMT
 Astria Therapeutics Q3 2025 Financial Results and Corporate Update  TradingView Wed, 12 Nov 2025 13:15:00 GMT
 price-driven insight from (atxs) for rule-based strategy  news.stocktradersdaily.com Mon, 10 Nov 2025 13:36:02 GMT
 astria reports positive results from navenibart hae trial by investing.com  Investing.com Nigeria Fri, 07 Nov 2025 07:35:19 GMT
 Astria Therapeutics (ATXS) Reveals Positive Phase 1b/2 Trial Res  GuruFocus Thu, 06 Nov 2025 18:29:40 GMT
 astria reports positive results from navenibart hae trial by investing.com  Investing.com South Africa Thu, 06 Nov 2025 13:26:00 GMT
 published on: 2025-11-06 03:49:04  newser.com Thu, 06 Nov 2025 09:49:04 GMT
 acquisition offer puts astria therapeutics shares in a tight spot  AD HOC NEWS Wed, 05 Nov 2025 08:44:05 GMT
 published on: 2025-11-04 23:55:39  newser.com Wed, 05 Nov 2025 05:55:39 GMT
 published on: 2025-11-01 00:43:15  newser.com Sat, 01 Nov 2025 05:43:15 GMT

Astria Therapeutics, Inc.
(NASDAQ:ATXS) 

ATXS stock logo

Catabasis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. The company's lead product candidate is QLS-215, a monoclonal antibody inhibitor of plasma kallikrein that is in preclinical development fo...

Founded: 2008
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends